Publications


In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
Neuro Oncol 2015 Aug 20;17(8):1086-94. Epub 2015 Jan 20.
Southern Alberta Cancer Research Institute, University of Calgary, Calgary, Canada (B.A.M., F.J.Z., A.N., X.L, E.U.K, P.A.F.); Department of Pediatrics, University of Calgary, Calgary, Canada (A.N.); Department of Oncology, University of Calgary, Calgary, Canada (A.N., P.A.F.); Department of Physiology & Pharmacology, University of Calgary, Calgary, Canada (E.U.K.); Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, Florida (A.P., R.S.K, P.A.F.); Department of Molecular Genetics & Microbiology, University of Florida, Gainesville, Florida (G.M.).

Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.
Neuro Oncol 2015 Jun 12;17(6):822-31. Epub 2014 Nov 12.
Division of Pediatric Oncology, Alberta Children's Hospital and POETIC Laboratory for Preclinical and Drug Discovery Studies, University of Calgary, Calgary, Alberta, Canada (Y.R., A.J., X.L., R.A., A.N.); Department of Biological Sciences, University of Lethbridge, Lethbridge, Canada (A.K., O.K.); Department of Pathology, Yokohama City University School of Medicine and Division of Diagnostic Pathology, Tokyo Women's Medical University Hospital, Tokyo, Japan (Y.N.); Department of Pathology and Laboratory Medicine, Alberta Children's Hospital and Calgary Laboratory Services, Calgary, Canada (J.R.W., A.P.); Department of Neurology, Alberta Children's Hospital, Calgary, Canada (A.K.).

Aurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents.
PLoS One 2014 21;9(7):e102741. Epub 2014 Jul 21.
Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) Laboratory for Pre-Clinical and Drug Discovery Studies, University of Calgary, Calgary, Alberta, Canada; Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada.

A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes.
Neuro Oncol 2014 Jan 4;16(1):62-71. Epub 2013 Dec 4.
Corresponding authors: Jennifer A. Chan, MD, Department of Pathology & Laboratory Medicine, University of Calgary, HRIC 2A25, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1. Annie Huang, MD, PhD, Division of Hematology-Oncology, Department of Pediatrics, The Hospital for Sick Children, TMDT, 11-401P, 101 College St., Toronto, Ontario, Canada M5G 1L7

Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
Cancer Res 2013 Nov 9;73(22):6734-44. Epub 2013 Sep 9.
Authors' Affiliations: Department of Pediatrics; Division of Anatomic Pathology, Department of Pathology and Laboratory Medicine; Division of Pediatric Neurosurgery, Department of Surgery, BC Children's Hospital, University of British Columbia; Department of Pathology and Laboratory Medicine, Centre for Applied Genomics, British Columbia Cancer Agency, Vancouver, British Columbia; Division of Neurosurgery, Department of Surgery, Faculty of Health Sciences, McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton; The Arthur and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick Children, Toronto, Ontario; Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) Laboratory for Pre-Clinical and Drug Discovery Studies, Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada; and Division of Pediatric Neuro-Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors.
Mol Oncol 2013 Oct 14;7(5):944-54. Epub 2013 Jun 14.
Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) Laboratory for Pre-Clinical and Drug Discovery Studies, University of Calgary, Canada and Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada.

Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.
Leuk Lymphoma 2013 Jul 29;54(7):1505-16. Epub 2012 Dec 29.
Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) Laboratory for Pre-Clinical and Drug Discovery Studies, University of Calgary, Calgary, AB, Canada.


Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.
Mol Oncol 2013 Jun 11;7(3):497-512. Epub 2013 Jan 11.
Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC), Laboratory for Pre-Clinical and Drug Discovery Studies, University of Calgary, Calgary, Alberta, Canada.

Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
Pediatr Blood Cancer 2012 Dec 8;59(7):1252-8. Epub 2012 Aug 8.
Kimmel Comprehensive Cancer Center at Johns Hopkins, The Bunting & Blaustein Cancer Research Building, Baltimore, MD 21231, USA.


Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition.
Cancer Cell Int 2011 Dec 29;11(1):44. Epub 2011 Dec 29.
Laboratory for Pre-clinical and Drug Discovery Studies, Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) and Division of Pediatric Oncology, Alberta Children's Hospital, 2888 Shaganappi Trail NW, Calgary, T3B 6A8, Canada.








Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
J Exp Ther Oncol 2008 ;7(3):183-93
Translational Research Laboratories, Tom Baker Cancer Centre and the Division of Pediatric Oncology Alberta Children's Hospital, Calgary, Alberta, Canada.



Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.
Pediatr Res 2005 Mar 19;57(3):430-7. Epub 2005 Jan 19.
Center for Experimental and Molecular Therapeutics for Childhood Cancers, Southern Alberta Children's Cancer Program, Alberta Children's Hospital, Calgary, Alberta T2T 5C7, Canada.


Purine nucleoside phosphorylase deficiency associated with a dysplastic marrow morphology.
Pediatr Res 2004 Mar 7;55(3):472-7. Epub 2004 Jan 7.
Division of Immunology and Allergy, The Hospital for Sick Children, 555 University Ave., Rm. 7279 Elm Wing, Toronto, Ontario, M5G 1X8, Canada.

OF